Specialty health sciences company Guardion Health Sciences (GHS) recently announced it has received a patent for its MapcatSF® diagnostic device from the U.S. Patent and Trademark Office.
MapcatSF is a non-mydriatic, non-invasive diagnostic device used to measure the density of macular protective pigment, providing eye care professionals the ability to accurately measure and monitor levels of macular carotenoids. The device, together with GHS' Lumega-Z®, provides an evidence-based protocol to manage the condition of a depleted macular pigment.
Click here to read the full press release.
Source: Guardion Health Sciences